Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-β treatment

Cytokine

Volumn 8, Issue 5, 1996, Pages 395-400

  Nicoletti, Ferdinando ^a   Patti, Francesco ^a   Di Marco, Roberto ^a   Zaccone, Paola ^a   Nicoletti, Alessandra ^a   Meroni, PierLuigi ^a   Reggio, Arturo ^a  

^a NONE

Author keywords

Interferon; Interleukins; Interleukins 1 receptor antagonist; Multiple sclerosis

Indexed keywords

BETA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; REMISSION;

ADOLESCENT; ADULT; HUMANS; INTERFERON-BETA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MIDDLE AGED; MULTIPLE SCLEROSIS; REMISSION, SPONTANEOUS; SIALOGLYCOPROTEINS;

EID: 0030015204     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1996.0054     Document Type: Article

References (50)

1. Adams CW, Poston RN, Buk SJ (1989) Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis. J Natural Sci 92:291.
2. Woodrofe MN, Bellamy AS, Feldmann M, Davison AN, Cuzner ML (1986) Immunocytochemical characterization of the immune reaction in the central nervous system in multiple sclerosis. Possible role for microglia in lesion growth. J Neurol Sci 74:135.
3. Hofman FM, von Hanwehr RI, Dinarello CA, Mizel SB, Hinton D, Merrill JE (1986) Immunoregulatory molecules and IL-2 receptors identified in multiple sclerosis brain. J Immunol 136:3239-3245.
4. Hafler DA, Weiner HL (1995) Immunologic mechanisms and therapy in multiple sclerosis. Immunol Rev 144:75-107.
5. Olsson T (1995) Critical influences of the cytokine orchestration on the outcome of mylein antigen-specific T cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 144:245-268.
6. Noseworthy JH (1994) Immunosuppressive therapy in multiple sclerosis: pros and cons. Int. MSJ 1:79-89.
7. Durelli L, Bongioanni MR, Cavallo R, Ferrero M, Ferri R, Ferrio MF, Bradac GD, Riva A, Vai S, Geuna M, Bergamini L, B ergamasco B (1994) Chronic systemic high-dose recombinant interferon-alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon-gamma production in relapsing remitting multiple sclerosis. Neurology 44:406-413.
8. Knobler RL, Panitch HS, Braheny SL, Sipe JC, Rice GPA, Huddlest JR, Francis GS, Hooper CJ, Kaminlew RM, Johnson KP (1984) Systemic alpha interferon therapy in multiple sclerosis. Neurology 34:1273-1279.
9. Camenga DL, Johnson KP, Alter M et al. (1986) Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol 43:1239-1246.
10. Panitch HS, Heracl RL, Schindler J, Johnson KP (1987) Treatment of multiple sclerosis with gamma-interferon: exacerbations associated with activation of the immune system. Neurology 37:1097-1120.
11. The Interferon-beta Multiple Sclerosis Study group (1993) Interferon-beta 1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661.
12. Paty DW, Li DKB, the UBC MS/MRI Study Group and the IFN-beta Multiple Sclerosis Study Group (1993) Interferon beta-1 beta is effective in relapsing-remitting multiple sclerosis. Neurology 43, 662-667.
13. The IFN-beta Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) Neurology 45:1277-1285.
14. Abreu SL (1982) Suppression of experimental allergic encephalomyelitis by interferon. Immunol Com 11:1-7.
15. Abreu SL, Tondreau J, Levine S, Sowinski R (1983) Inhibition of passive localized allergic encephalomyelitis by interferon. Int Arch Allergy Appl Immunol 72:30-33.
16. Hertz F, Deghenghi R (1985) Effect of rat and beta human interferon on hyperacute experimental allergic encephalomyelitis in rats. Agents Actions 16:397-403.
17. Noronha A, Toscas A, Jensen MA (1990) Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 27:207-210.
18. Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PL, Teitelbaum AP, Smalley RV, Borden EC (1989) Human biologic response modification by interferon in absence of measurable serum concentrations: A comparative study of subcutaneous and intravenous interferon-beta serine. J Natl Cancer Inst 81:1061-1068.
19. Barna BP, Chou SM, Jacobs B et al (1989) Interferon-beta impairs induction of HLA-DR antigen expression in cultured human astrocytes. J Neuroimmunol 23:45-53.
20. Huynh HK, Oger J, Dorovini-Zis K (1995) Interferon-beta downregulates interferon-gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells. J Neuroimmunol 60:63-73.
21. Traugott U, Scheinberg LC, Raine CS (1985) On the presence of la-positive EC and astrocytes in multiple sclerosis lesions and its relevance to antigen presentation. J Neuroimmunol 8:1-14.
22. Mandrup-Poulsen T, Pociot F, Molvig J, Shapiro L, Nilsson P, Emdal T, Roder M, Kjems LL, Dinarello CA, Nerup J (1994) Monokine antagonism is reduced in patients with IDDM. Diabetes 43:1242-1247.
23. Bendtzen K (1989) Immune hormones (cytokines); pathogenicrole in autoimmune rheumatic diseases and endocrine diseases. Autoimmunity 2:177-189.
24. Bendtzen K. Cytokines and natural regulators of cytokines. Immunol Letters 43:111-123.
25. Eisenberg SP, Evans RJ, Arend WP, Verderberr E, Brewer MT, Hannum CH, Thompson RC (1990) Primary structure and functional expression of from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343:341-346.
26. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, Armes LG, Sommer A, Eisenberg SP, Thompson RC (1990) Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343:336-340.
27. Dinarello CA (1991) Interleukin-1 and interleukin-1 antagonism. Blood 77:1627-1652.
28. Casini-Riggi V, Kam L, Chong YJT, Fiochhi C, Pizzarro T, Cominelli F (1995) Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 154:2434-2440.
29. Miller LC, Lynch EA, Isa S, Logan JW, Dinarello CA, Steere AC (1993) B alance of synovial fluid IL-1 beta and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet 341:146-148.
30. Chomarat P, Vannier E, Dechanet J, Rissoan MC, Bancherau J, Dinarello CA, Miossec P (1995) Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 154:1432-1439.
31. Gruss HJ, Doelken G, Brach MA, Herrmann F (1992) High concentration of the interleukin-1 receptor antagonist in serum of patients with Hodgkin's disease. Lancet 340:968.
32. Firestein GS, Berger AE, Tracey DE, Chosay JC, Chapman DL, Paine MM, Yu C, Zvaifler NJ (1992) IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol 149:1054-1062.
33. Tsukada N, Matsuda M, Miyagi K, Yanagisawa N (1993) Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology 43:2679-2682.
34. Jenkins JP, Arend WP (1993) Interleukin and receptor autagonist production in human monocytes is induced by IL-1α, IL-3, IL-4 and GM-CSF. Cytokine 5:407-415.
35. Tilg H, Mier JM, Vogel W, Aulitzky WE, Wiedermann CJ, Vannier E, Huber C, Dinarello CA (1993) Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 50:4687-4692.
36. Roux-Lombard P, Modoux C, Dayer J-M (1989) Production of interleukin-1 (IL-1) and a specific IL-inhibitor during human monocyte-macrophage differentiation: influence of GM-CSF. Cytokine 1:45-51.
37. Vannier E, Miller LC, Dinarello CA (1992) Coordinated antiinflammatory effects of interleukin-4: interleukin-4 suppresses interleukin-1 production but up-regulates gene expression and synthesis of interleukin-1 receptor antagonist. Proc Natl Acad Sci USA 89:4076-4080.
38. Matsuda M, Tsukada N, Iyagi K, Yanagisawa N (1991) Increased Interleukin-1 production by peripheral blood mononuclear cells in patients with multiple sclerosis. J Neurol Sci 102:100-104.
39. Gallo P, Piccinno MG, Pagni S, Argentiero V, Giometti B, Bozza F, Tavolato B (1989) Immune activation in multiple sclerosis: Study of IL-2, sIL-2R and gamma-IFN levels in serum and cerebrospinal fluid. J Neurol Sci 92:9-15.
40. Olsson T, Wang WZ, Hojeberg B, Kostulas V, Jang YP, Anfersson G, Ekre HP, Link H (1990) Autoreactive T lymphocytes in multiple sclerosis determined by antigen induced secretion of interferon-gamma. J Clin Invest 86:981-985.
41. Frei K, Fredrikson S, Fontana A, Link H (1991) Interleukin-6 is elevated in plasma multiple sclerosis. J Neuroimmunol 31:147-153.
42. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alfa and disease progression in patients with multiple sclerosis. New Engl J Med 325:467-472.
43. Jacobs CA, Baker PE, Roux ER, Picha KS, Toivola B, Waugh S, Kennedy MK (1991). Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alfa and suppressed by soluble IL-1 receptor. J Immunol 146:2983-2989.
44. McCarthy PL, Abhyankar S, Neben S, Newman G, Sieff C, Thompson RC, Burakoff SJ, Ferrara JLM (1991). Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft versus host disease. Blood 78:1915-1918.
45. Dayer-Metroz MD, Duhamel D, Rufer N, Izui S, Carmichaels D, Wollheim CB, Thompson RC, Dayer JM (1992). IL-1 receptor antagonist delays spontaneous autoimmune diabetes in BB rats. Eur J Clin Invest 22 A50 (abstract).
46. Wooley PH, Whalen JD, Chapman DL, B erger AE, Richard KA, A spar DG, Staite ND (1993) The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 36:1305-1314.
47. Cominelli F, Nast CC, Clark BD, Schindler R, Llerena R, Eysselein VE, Thompson RC, Dinarello CA (1990). Interleukin-1 (IL-1) gene expression, synthesis and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 86:972-980.
48. Martin D, Near SL (1995) Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J Neuroimmunol 61:241-245.
49. Granowitz EV, Porat R, Mier JM, Pribble JP, Stiles DM, Bloedow DC, Catalano MA, Wolff SM, Dinarello CA (1992). Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 4:353-360.
50. Poser CM, Paty DW, Scheinberg L, McDonald I, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourrellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231.